PD-1/PD-L1-IN 3 (TFA)
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases[1].
Product Specifications
UNSPSC
12352209
Target
PD-1/PD-L1
Type
Peptides
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pd-1-pd-l1-in-3-tfa.html
Purity
99.96
Solubility
H2O : 50 mg/mL (ultrasonic)
Smiles
Molecular Formula
C91H127F3N24O20S
Molecular Weight
1966.19
References & Citations
[1]MILLER, Michael Matthew, et al. Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1) /pd-l1 protein/protein interactions. WO2014151634A1.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Browse additional items from our catalog
KCNJ18, NT (KCNJ18, Inward rectifier potassium channel 18, Inward rectifier K(+) channel Kir2.6, Potassium channel, inwardly rectifying subfamily J member 18) (MaxLight 650)
